Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.

Bianco, Roberto

Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Jul 2004 - 4858-64 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1078-0432

10.1158/1078-0432.CCR-03-0497 doi


Animals
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Blotting, Western
Cell Line, Tumor
Cell Proliferation--drug effects
Dose-Response Relationship, Drug
Drug Synergism
ErbB Receptors--metabolism
Fibroblast Growth Factor 2--biosynthesis
Gefitinib
Humans
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Mitogen-Activated Protein Kinases--metabolism
Nuclear Proteins--genetics
Oligonucleotides, Antisense--pharmacology
Phosphorylation--drug effects
Prostatic Neoplasms--metabolism
Protein Biosynthesis--drug effects
Protein Serine-Threonine Kinases--metabolism
Proto-Oncogene Proteins--genetics
Proto-Oncogene Proteins c-akt
Proto-Oncogene Proteins c-mdm2
Quinazolines--pharmacology
Time Factors
Vascular Endothelial Growth Factor A--biosynthesis
Xenograft Model Antitumor Assays